After months of hard work, NOETIK is thrilled to announce that we've emerged from stealth mode.
Follow us for more updates on how we plan to leverage advanced machine learning methods to discover and develop cancer immunotherapies.
NOETIK
91 posts
NOETIK
@NOETIK_ai
Frontier models of human biology.
- New on the NOETIK blog: “What’s the point of virtual cells?” The first in a series of upcoming posts to unpack our unique view of virtual cell models, and most importantly how they can be used to solve real life therapeutics problems for patients.How do you use a virtual cell to do something actually useful? (1/3) Right now, many groups are building virtual cells. The concept is exciting, but the question on everyone's mind remains: what's the point? We at Noetik have decided to answer that question, via three case
- We’re excited to announce the collaboration between @Agenus_Bio and Noetik to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology. Read more here:businesswire.com/news/home/2025…
- We’re excited to welcome Lisa Ryan as Noetik’s new Chief People Officer! Lisa’s systems-driven, deeply human approach will help us strengthen the foundation of Noetik. We’re thrilled to have her on board as we continue to grow our team and mission.
- We are excited to announce that five distinguished leaders have joined the Noetik Scientific Advisory Board: Dr. Vijay Kuchroo, Dr. Matthew Albert, Dr. William Grossman, Dr. Marcia Belvin and Dr. Kwok-Kin Wong.
- We are building one of the most significant oncology datasets in the industry, fit for purpose for AI, with seamless connectivity between human data and scaled in vivo functional genomics/pharmacology.Announcement! @noetik_ai team are excited to launch a powerful new second(!) platform that connects seamlessly with our human platform to add powerful discovery capabilities... See press release and thread below👇 businesswire.com/news/home/2023…
- Our CEO, @ronalfa , recently sat down with the New York Stock Exchange team to talk about how Noetik is building the next generation of AI-native drug discovery, combining rich multimodal patient data with virtual cell foundation models.LIVE on NYSE TV 🎙️ Hear top market data from @KennyPolcari. Plus, the AI Bio Summit takes place at NYSE today – @ronalfa of @NOETIK_ai talks emerging tech to combat cancer & @definevc shares data from a new survey on pharma leaders and the AI vision. x.com/i/broadcasts/1…
- Joining Noetik owlposting.com/p/joining-noet… after a restful month of funemployment, i joined @NOETIK_ai last week. this essay explains my current beliefs about the ML-bio field, why I joined Noetik, and what they are working on 2.8k words, 14 minutes reading time
- Great coverage of our collaboration with @Agenus_Bio to use Virtual Cell Models of patient biology to impact clinical success. Together, we are directing the most advanced AI in biology to tackle real therapeutics challenges for patients.
- NOETIK is proud to partner with @DCVC as our lead investor on our mission to use AI to develop precision cancer immunotherapies.
- The NOETIK team will be presenting cutting-edge work at the @sitcancer Society for Immunotherapy of Cancer Annual Meeting 2025 in National Harbor, MD. We have two exciting presentations demonstrating the power of our Foundation Models to transform our understanding of cancer.
- This Wednesday, Sept. 17 at 12:00 p.m. ET, our CEO @ronalfa will join The Washington Post Live: Chasing Cancer - Advancing Tech for a conversation on how emerging technologies in AI are reshaping diagnostics, precision medicine, and cancer care.
- We’re proud to be featured in NVIDIA’s latest blog highlighting RAPIDS and the future of scalable single-cell analysis. At NOETIK, we're building first-in-class virtual cell models trained on hundreds of millions of cells worth of patient data.
